Theriva Biologics (TOVX) Share-based Compensation (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Share-based Compensation of $135000.0 for Q1 2026, up 35.0% year-over-year from $100000.0 in Q1 2025, and down 11.76% quarter-over-quarter from $153000.0 in Q4 2025.
Theriva Biologics (TOVX) Share-based Compensation (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Share-based Compensation for 17 consecutive years, with $135000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 35.0% year-over-year to $135000.0; the TTM figure through Mar 2026 stood at $689000.0 (up 12.77% YoY), while the FY2025 annual figure was $694000.0, up 3.43% from the prior year.
- Share-based Compensation declined to $135000.0 in Q1 2026 per TOVX's latest filing, from $153000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $228000.0 in Q3 2025 and bottomed at $100000.0 in Q1 2025.
- Historically, Share-based Compensation has averaged $146294.1 across 5 years, with a median of $145000.0 in 2023.
- Annual changes were most pronounced in 2025 — Share-based Compensation slumped 37.5% — and 2026, when it surged 35.0%.
- Theriva Biologics' Share-based Compensation stood at $129000.0 in 2022, then advanced by 12.4% to $145000.0 in 2023, then increased by 11.72% to $162000.0 in 2024, then dropped by 5.56% to $153000.0 in 2025, then dropped by 11.76% to $135000.0 in 2026.
- Business Quant data shows TOVX's Share-based Compensation at $135000.0 in Q1 2026, $153000.0 in Q4 2025, and $228000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Theriva Biologics | 10.90 Mn | 10.90 Mn | - | 693,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 693,000.00 |
| Jun 30, 2026 | 693,000.00 |
| Mar 31, 2026 | 135,000.00 |
| Mar 31, 2026 | 135,000.00 |
| Dec 31, 2025 | 153,000.00 |
| Dec 31, 2025 | 153,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Jun 30, 2025 | 173,000.00 |
| Jun 30, 2025 | 173,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 162,000.00 |
| Dec 31, 2024 | 162,000.00 |
| Sep 30, 2024 | 177,000.00 |
| Sep 30, 2024 | 177,000.00 |
| Jun 30, 2024 | 172,000.00 |
| Jun 30, 2024 | 172,000.00 |
| Mar 31, 2024 | 160,000.00 |
| Mar 31, 2024 | 160,000.00 |